Industry Voice: China health care innovation

Why are we so excited by drug innovation in China?

clock • 1 min read
Industry Voice: China health care innovation

For Professional Clients only

 

Initiatives to stimulate innovation, especially around drug research and development (R&D), have been the most impactful, in our view.

The result is a booming drug R&D ecosystem including quality biotechs and their R&D outsourcing partner companies.

We expect reforms to provide tremendous industry tailwinds for the next decade and, as long-term investors in this space, we are excited about the new opportunities that are being created.

 

 

 

Investment risks

The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.

Important information

This article is for Professional Clients only and is not for consumer use.

Where individuals or the business have expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.

Issued by Invesco Asset Management Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK. Authorised and regulated by the Financial Conduct Authority.

Advertisement

More on Emerging markets

Vietnamese equities tend to outperform Chinese equities when Chinese equities underperform the rest of the world

Deep Dive: Frontier markets require caution due to 'barrage' of shocks

Divergence from emerging markets

Kathleen Gallagher
clock 12 August 2022 • 4 min read
European-focused investment grade and high yield credit have highest inflows since April 2020.

Fixed income dominates ETF flows in July

Accounted for $32.5bn

clock 08 August 2022 • 2 min read
Industry Voice: Mapping China's recovery

Industry Voice: Mapping China's recovery

2021 was a record year for dividends around the globe Our EMEA ETF Investment Strategy team believes that while Chinese equities may need to consolidate in the short-term, the recovery since the March 2022 low remains on track.

Franklin Templeton
clock 03 August 2022 • 3 min read
Trustpilot